Hematología y Hemoterapia

Resultados: 405
Tipo Título / Nombre Autor(es) Año
Post-Remission Treatment with Chemotherapy or Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) in Adult Patients with High-Risk (HR) Philadelphia Chromosome-Negative (Ph-neg) Acute Lymphoblastic Leukemia (ALL) According to Their Minimal Residual Disease (MRD). Final Results of the Pethema ALL-HR-11 Trial Ribera JM, Morgades M, Prob M, Ciudad J, Montesinos P, Barba P, et al 2019
Update on management and progress of novel therapeutics for R/R AML: an Iberian expert panel consensus Montesinos P, Bergua J, Infante J, Esteve J, Guimaraes JE, Sierra J, et al 2019
Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia Lozano ML, Mingot-Castellano ME, Perera MM, Jarque I, Campos-Álvarez RM, González-López TJ, et al 2019
Evolution of myeloid-derived suppressor cells and objective response rate in relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL) patients after receiving immunotherapy Jiménez Cortegana C, Palazón Carrión N, Nogales Fernández E, Nieto García MA, Sánchez Margalet V, Alamo de la Gala MDC, et al 2019
Clinicobiologic characteristics and outcome of elderly frail patients with acute lymphoblastic leukemia included in a specific protocol (all-07FRAIL) Ribera JM, García Calduch O, Gil C, González Campos J, Moreno MJ, Barba P, et al 2019
Differences in ex-vivo Chemosensitivity to Anthracyclines in First Line Acute Myeloid Leukemia Megías-Vericat JE, Martínez-Cuadrón D, López JM, Bergua JM, Tormo M, Serrano J, et al 2019
Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature Rodríguez-Otero P, Mateos MV, Martínez-López J, Hernández MT, Ocio EM, Rosiñol L, et al 2019
DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy Sánchez-Correa B, Valhondo I, Hassouneh F, López-Sejas N, Pera A, Bergua JM, et al 2019
High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by a three-year rituximab maintenance García-Marco JA, López Jiménez J, Recasens V, Fernández Zarzoso M, González-Barca E, Somolinos De Marcos N, et al 2019
Identification of novel variants in ten patients with Hermansky-Pudlak syndrome by high-throughput sequencing Bastida JM, Morais S, Palma-Barqueros V, Benito R, Bermejo N, Karkucak M, et al 2019